Behavioral and neurobiological changes in a novel mouse model of schizophrenia induced by the combination of cuprizone and MK-801.

Brain Research Bulletin
Zheng-Yu SunLin Li

Abstract

Schizophrenia is a mental illness characterized by episodes of psychosis, apathy, social withdrawal, and cognitive impairment. White matter lesions and glutamatergic hypofunction are reported to be the key pathogeneses underlying the multiple clinical symptoms of schizophrenia. Cuprizone (CPZ) is a copper chelator that selectively injures oligodendrocytes, and MK-801 is an antagonist of the N-methyl d-aspartate (NMDA) receptor. To better mimic the psychosis and complicated pathogenesis of schizophrenia, a novel possible mouse model was established by the combination of CPZ and MK-801. After exposure to CPZ for 5 weeks, the mice received a daily intraperitoneal injection of MK-801 for 2-weeks. Behavioral changes in the mouse model were evaluated using Y-maze, object recognition, and open field tests. Pathological changes were observed by transmission electron microscopy, oil red O staining, immunohistochemistry, and western blotting. The results showed that the novel mouse model induced by CPZ plus MK-801 exhibited severe spatial and recognition memory deficits, hyperactivity, and anxiety disorder. Moreover, the mice showed obvious demyelination and white matter damage and decreased expression levels of myelin basic protein (MBP...Continue Reading

References

Mar 17, 2000·Brain Research. Brain Research Reviews·J H Meador-Woodruff, D J Healy
Feb 14, 2006·British Journal of Pharmacology·Philip E Chen, David J A Wyllie
Jun 24, 2006·Cellular and Molecular Life Sciences : CMLS·J M Boggs
May 22, 2007·Dalton Transactions : an International Journal of Inorganic Chemistry·Luigi MessoriPaolo Zatta
Jun 10, 2008·Trends in Neurosciences·R Douglas Fields
Apr 1, 2009·Behavioral Neuroscience·Haiyun XuXin-Min Li
Sep 25, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Bo LiEffat S Emamian
Oct 17, 2012·Molecular Psychiatry·C S WeickertT W Weickert
Apr 9, 2013·The Journal of Clinical Psychiatry·Brian Kirkpatrick
Jul 6, 2014·Neuropharmacology·Se Jin ParkJong Hoon Ryu
Mar 31, 2015·Evidence-based Complementary and Alternative Medicine : ECAM·Abulimiti AdilijiangXinMin Li
Jan 19, 2016·Lancet·Michael J OwenPreben B Mortensen
Sep 14, 2016·Early Intervention in Psychiatry·Tom A HummerAlan Breier
Sep 17, 2016·Drug Development Research·Nadja P MaricCedo Miljevic
Jan 12, 2017·Cell Reports·Nicolas SnaideroMikael Simons
Feb 1, 2017·Neurotoxicity Research·Marta Kruk-SlomkaGrazyna Biala
May 23, 2017·Psychological Medicine·M A Di BiaseA Zalesky
Jun 1, 2017·NPJ Schizophrenia·Kazu NakazawaKazuhito Nakao
Apr 17, 2018·NeuroImage·Yuchao JiangDezhong Yao
May 11, 2018·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Ian R WinshipJohn G Howland
Mar 31, 2019·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ane Murueta-GoyenaHarkaitz Bengoetxea

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.